Welgene Biotech Co.Ltd.
Welgene Biotech Co.,Ltd. engages in the trade of biotechnology-related instruments, reagents, and biotechnology testing services. The company offers research services, including generation, PacBio third generation sequencing; microarray, protein body analysis; nucleic acid extraction/QC, single cell experimental, and bioinformatics analysis services. It also provides reagents, medical consumables… Read more
Welgene Biotech Co.Ltd. (6661) - Total Liabilities
Latest total liabilities as of September 2025: NT$261.11 Million TWD
Based on the latest financial reports, Welgene Biotech Co.Ltd. (6661) has total liabilities worth NT$261.11 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Welgene Biotech Co.Ltd. - Total Liabilities Trend (2014–2024)
This chart illustrates how Welgene Biotech Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Welgene Biotech Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Welgene Biotech Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Visa Steel Limited
NSE:VISASTEEL
|
India | ₹19.06 Billion |
|
Hochdorf Holding AG
SW:HOCN
|
Switzerland | CHF2.24 Million |
|
Goodyear Indonesia Tbk
JK:GDYR
|
Indonesia | Rp846.81 Billion |
|
Gibb River Diamonds Limited
F:PHO
|
Germany | €363.93K |
|
Sadbhav Infrastructure Project Limited
NSE:SADBHIN
|
India | ₹56.20 Billion |
|
Original Juice Co. Ltd.
AU:OJC
|
Australia | AU$27.53 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Welgene Biotech Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Welgene Biotech Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Welgene Biotech Co.Ltd. (2014–2024)
The table below shows the annual total liabilities of Welgene Biotech Co.Ltd. from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$232.50 Million | -6.21% |
| 2023-12-31 | NT$247.89 Million | +88.14% |
| 2022-12-31 | NT$131.76 Million | +15.10% |
| 2021-12-31 | NT$114.47 Million | +6.44% |
| 2020-12-31 | NT$107.54 Million | -37.29% |
| 2019-12-31 | NT$171.50 Million | +48.11% |
| 2018-12-31 | NT$115.79 Million | +31.02% |
| 2017-12-31 | NT$88.37 Million | +22.24% |
| 2016-12-31 | NT$72.30 Million | -11.62% |
| 2015-12-31 | NT$81.80 Million | -24.43% |
| 2014-12-31 | NT$108.24 Million | -- |